Oprozomib and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma: Initial Results from the Dose Escalation Portion of a Phase 1b/2, Multicenter, Open-Label Study
Parameswaran Hari(Medical College of Wisconsin), Claudia Prada(Dana-Farber Cancer Institute), Paul G. Richardson(Harvard University), Kenneth H. Shain(Moffitt Cancer Center), Muneer H. Abidi(Spectrum Health), Linda Neuman, Peter M. Voorhees(Levine Cancer Institute), Nashat Gabrail(Gabrail Cancer Center), Sandra Dixon(Amgen (United States)), Ralph V. Boccia(Center for Cancer and Blood Disorders), Jeffrey A. Zonder(The Barbara Ann Karmanos Cancer Institute)
Cited by 18
Related Papers
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
|New England Journal of Medicine|2003|2.6k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
|New England Journal of Medicine|2016|1.1k